A First-in-Human, Randomized, Double-Blind, Placebo-Controlled, Sequential-Panel, Ascending Single- and Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZ-3102 in Healthy Volunteers
Latest Information Update: 29 Jan 2024
At a glance
- Drugs Nizubaglustat (Primary)
- Indications Lysosomal storage diseases
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Azafaros
Most Recent Events
- 23 Jan 2024 According to an Azafaros media release, the results from this trial was recently published in the leading peer-reviewed journal, Molecular Genetics and Metabolism.
- 14 Feb 2022 According to an Azafaros media release, data from this study was presented at the 18th Annual WORLD Symposium.
- 14 Feb 2022 Results published in an Azafaros Media Release.